Healthcare Resource Utilization in Refractory MACLD: Comparison of an Amikacin Liposome Inhalation Suspension (ALIS) Cohort with a Non-ALIS Cohort
Add-on treatment with ALIS in refractory MACLD may lead to reductions in hospitalizations over time and lower odds of hospitalizations compared with add-on treatment with non-ALIS antibiotics.
Authors
- Emily J. Welch
- Timothy R. Aksamit (ORCID: https://orcid.org/0000-0002-5243-5394)
- Catherine Waweru
- Ping Wang (ORCID: https://orcid.org/0000-0003-0286-4083)
- Leona E. Markson
- Elsie Divinagracia
Institutions
- Insmed (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1007/s41030-025-00324-z
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Insmed